March 27 (Bloomberg) -- Merck & Co.'s Singulair may be linked to suicide as well as changes in mood and behavior, U.S. regulators said today in announcing a review of the company’s top-selling asthma drug. The Food and Drug Administration is working with Whitehouse Station, New Jersey-based Merck to evaluate studies and patient reports, the agency said today in a notice on its Web site. The examination may take as long as nine months, the FDA said. The company declined to say how many deaths were reported.
